Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4703482 | 0.86 | DAO (0.55) | CA1CA2MAPTKDM4EGLA | |
| SCHEMBL28147113 | 0.83 | MEN1 (0.39) | CA2MAPTL3MBTL1RAB9AALDH1A1 | |
| SCHEMBL7031481 | 0.83 | CTPS1 (0.39) | OPRD1CA1CA2CTPS1MAPT | |
| SCHEMBL27953727 | 0.82 | CTPS1 (0.39) | OPRD1CA1CA2CTPS1MAPT | |
| SCHEMBL26998951 | 0.82 | CTPS1 (0.39) | OPRD1CA1CA2CTPS1MAPT | |
| SCHEMBL8627970 | 0.82 | HPGD (0.47) | CA1CA2MAPTKDM4EL3MBTL1 | |
| SCHEMBL18302448 | 0.82 | MAPT (0.52) | MAPTKDM4EL3MBTL1RAB9AHPGD | |
| SCHEMBL25399545 | 0.80 | KMT2A (0.54) | CA1CA2MAPTATMHPGD | |
| SCHEMBL3055932 | 0.80 | MEN1 (0.37) | CA2MAPTKDM4EL3MBTL1RAB9A | |
| SCHEMBL6881198 | 0.79 | OPRD1 (0.56) | OPRD1CA1CA2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365584-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHRÖDINGER, INC. | 2023-11-16 | — | — | US | disclosed |
| CN-116490507-A | Heterocyclic condensation CDC7 kinase inhibitors for the treatment of cancer | 薛定谔公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-4211140-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Schrödinger, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2022055963-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHRÖDINGER, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365584-A1 | HETEROCYCLIC PERICONDENSED CDC7 KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CDC7, BUB1B, CDK7 | OPRD1 4375/4885CA1 3661/4885CA2 3234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.